You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00573170 ↗	TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults	Completed	GlaxoSmithKline	Phase 3	2008-02-01	Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

Condition Name

Chart
Table

Condition Name for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Intervention	Trials
Migraine, Acute	1
Migraine Disorders	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Intervention	Trials
Migraine Disorders	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

Trials by Country

Map
Table

Trials by Country for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Location	Trials
United States	33
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Location	Trials
Mississippi	1
Michigan	1
Massachusetts	1
Maryland	1
Maine	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Clinical Trial Phase	Trials
Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Clinical Trial Phase	Trials
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

Sponsor Name

Chart
Table

Sponsor Name for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Sponsor	Trials
GlaxoSmithKline	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Sponsor	Trials
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.